Skip to content

An observational study on the relationship between intestinal microflora and hemodynamic response of non selective beta blockers

An observational study on the relationship between intestinal microflora and hemodynamic response of non selective beta blockers

Status
Recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2000032755
Enrollment
Unknown
Registered
2020-05-09
Start date
2020-05-01
Completion date
Unknown
Last updated
2020-05-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Intestinal flora and portal hypertension

Interventions

case series:NSBBs

Sponsors

Nanjing Drum Tower Hospital The Affiliated Hospital of Nanjing University Medical School
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. The patients with liver cirrhosis (according to clinical, laboratory, imaging, or liver biopsy) have been measured for the first time; 2. The patients with HVPG > 12mmhg and planned to take non selective ß receptor blocker; 3. Patients who had no history of gastrointestinal bleeding or esophageal varices bleeding before, and 5 days after acute bleeding; 4. Patients with moderate or severe esophageal and gastric varices confirmed by gastroscope; 5. Patients aged 18-75; 6. Patients willing to sign informed consent.

Exclusion criteria

Exclusion criteria: 1. Patients taking nsbbs or other drugs to treat portal hypertension in the past 6 weeks; 2. Patients with persistent bacterial infection requiring antibiotic treatment; 3. Patients who used antibiotics or immunomodulators in the past 2 weeks; 4. Patients taking microecological preparations in the past 6 weeks; 5. Patients with alcohol intake or illicit drug abuse in the past 6 weeks; 6. Patients with contraindications to use nsbbs, such as bronchial asthma, cardiogenic shock, heart block (II - III degree atrioventricular block), severe or acute heart failure and sinus bradycardia; 7. Patients taking drugs that affect the metabolism and absorption of nsbbs at the same time; 8. Patients with liver cancer or extrahepatic tumor; 9. Patients with severe heart, lung, liver and kidney dysfunction, or severe bleeding disease or local / systemic infection, hypothyroidism, Raynaud's syndrome, peripheral vascular disease, etc; 10. Patients with severe portal vein thrombosis; 11. Women who plan to be pregnant or who have been pregnant or breastfeeding.

Design outcomes

Primary

MeasureTime frame
Intestinal flora;HVPG response of NSBBs;

Countries

China

Contacts

Public ContactZhuge Yuzheng

Department of Gastroenterology, Gulou Hospital affiliated to Nanjing University School of Medicine

yuzheng9111963@aliyun.com+86 15996289206

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026